Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer

• DOI: 10.1016/j.lungcan.2023.107326
• Publication Date: 2023-08-11T06:40:13Z
• Authors: Jing Zheng; Yuekang Li; Chenghua Jin; Kexin Ruan; Ke Sun; Hao Chen; Meng Wang; Shumeng Zhang; Jianya Zhou; Jianying Zhou
• Keywords: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Antineoplastic Combined Chemotherapy Protocols; Humans; Cisplatin; 3. Good health; Retrospective Studies

Neoadjuvant immunochemotherapy is effective in resectable NSCLC. However, its role unresectable stage IIIB NSCLC patients remains controversial. This study aimed to demonstrate the efficacy and safety of neoadjuvant followed by surgical resection treat initial patients.This retrospectively analyzed 59 who received induction pembrolizumab combined with chemotherapy between June 2019 April 2022. Clinical characteristics, radiological pathological responses, survival outcomes were collected evaluated.Fifity-nine identified divided into surgery (n = 23) non-surgery 36) groups a median follow-up time 15.0 months. The PFS/DFS group was significantly longer than (not reached vs. 15.5 months, p 0.0031). overall (OS) not both groups, OS rate 100% (23/23) 83.3% (30/36) group. analysis suggested that 13 23 (56.5%) achieved major response (MPR) or complete (pCR), more squamous cell carcinoma cases observed MPR compared non-MPR (p 0.034). All had an R0 resection, no surgical-related mortality recorded; only three (13.0%) experienced any postoperative complications.In this retrospective study, after promising for patients, high good safety.